B+
Bull case
30%
Probability
Target price
$270.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
DHR
DanaherANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$249.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$195.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-26
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+66.3
Score
AI commentary
The Q3 company release and reported analyst target raises support a positive thesis update from the May baseline. The reported $233.86 October 21 close had eased to the packet's $230.50 October 23 anchor, however, so the first-day reaction did not fully hold. Consensus revenue comparisons conflict across secondary sources; only the $1.92 EPS consensus is used. Forward-estimate revisions, options, short-interest and sufficient social coverage were not established; zero sentiment-field values indicate unavailable data, not neutral measurements. [#SEC-8K-2026-10-21] Price history
RankAlpha Sentiment Codex - 2026-10-26
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-11-20catalystQ3 beat-and-raise follow-throughMedium impact
Danaher reported Q3 revenue of $6.6 billion, adjusted EPS of $2.11, 5.5% core growth excluding respiratory testing, and $1.6 billion of free cash flow. It raised 2026 adjusted EPS guidance to $8.57–$8.62 from $8.45–$8.60. The near-term test is whether the initial post-print advance holds; the October 23 anchor of $230.50 is below the reported October 21 close of $233.86. [#8-K-2026-10-21] [#SEC-8K-2026-10-21]
2026-12-31eventFourth-quarter underlying growth versus respiratory dragMedium impact
Danaher forecasts fourth-quarter core revenue growth of 4%–5% excluding respiratory revenue, but about 3% including an approximately 150-basis-point respiratory headwind. Sustaining the stronger underlying trend while delivering the raised EPS range is the next operating test. [#SEC-8K-2026-10-21]
2027-12-31catalystMasimo and StatLab integrationMedium impact
The supplied October 2026 10-Q relationship-context excerpts identify Masimo as acquired on June 10 and StatLab as acquired on September 28. The forward issue is integration, Diagnostics growth and returns on acquisition spending—not regulatory closing, which the prior baseline still treated as pending. [#10-Q-2026-10-21]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-26 • Updated nightlySource: Internal modelMethodology